武田-话题@MedSci

#武田#

91篇内容 | 3011人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1517253, encodeId=3510151e253df, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田的维多珠单抗在国内获批，用于治疗中度至重度活动性溃疡性结肠炎和克罗恩病, objectType=article, longId=190829, objectId=44d119082920, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44d119082920, replyNumber=0, likeNumber=68, createdTime=2020-03-27, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44d119082920, moduleTitle=武田的维多珠单抗在国内获批，用于治疗中度至重度活动性溃疡性结肠炎和克罗恩病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=44d119082920)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517252, encodeId=09d8151e25206, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田开始研发血浆衍生的COVID-19疗法, objectType=article, longId=189407, objectId=e09618940e20, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e09618940e20, replyNumber=0, likeNumber=65, createdTime=2020-03-07, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e09618940e20, moduleTitle=武田开始研发血浆衍生的COVID-19疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e09618940e20)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517251, encodeId=d2eb151e25148, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田宣布以3.3亿美元收购PvP Biologics，获得针对乳糜泻的I期临床药物TAK-062, objectType=article, longId=189174, objectId=b42d1891e483, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b42d1891e483, replyNumber=0, likeNumber=92, createdTime=2020-03-04, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b42d1891e483, moduleTitle=武田宣布以3.3亿美元收购PvP Biologics，获得针对乳糜泻的I期临床药物TAK-062, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b42d1891e483)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517250, encodeId=b443151e2501c, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田制药宣布FDA接受其补充新药申请并给予优先审查，将酪氨酸激酶抑制剂ALUNBRIG用作ALK +转移性非小细胞肺癌的一线治疗, objectType=article, longId=188797, objectId=3aed188e972f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3aed188e972f, replyNumber=0, likeNumber=30, createdTime=2020-02-27, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3aed188e972f, moduleTitle=武田制药宣布FDA接受其补充新药申请并给予优先审查，将酪氨酸激酶抑制剂ALUNBRIG用作ALK +转移性非小细胞肺癌的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3aed188e972f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517249, encodeId=a9ef151e2491e, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田的Entyvio单抗皮下制剂治疗溃疡性结肠炎，惨遭FDA拒绝, objectType=article, longId=185210, objectId=a0e3185210c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0e3185210c6, replyNumber=0, likeNumber=68, createdTime=2019-12-26, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0e3185210c6, moduleTitle=武田的Entyvio单抗皮下制剂治疗溃疡性结肠炎，惨遭FDA拒绝, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0e3185210c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517248, encodeId=90a4151e2483c, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田全新机制抑酸药物沃克®（富马酸伏诺拉生片）获批进入中国, objectType=article, longId=185201, objectId=b2f618520141, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2f618520141, replyNumber=0, likeNumber=86, createdTime=2019-12-26, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2f618520141, moduleTitle=武田全新机制抑酸药物沃克®（富马酸伏诺拉生片）获批进入中国, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2f618520141)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517247, encodeId=d2f2151e2475e, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田登革热疫苗在大规模的3期临床试验中有效率达80％, objectType=article, longId=182563, objectId=72bc182563be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=72bc182563be, replyNumber=0, likeNumber=82, createdTime=2019-11-09, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=72bc182563be, moduleTitle=武田登革热疫苗在大规模的3期临床试验中有效率达80％, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=72bc182563be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517246, encodeId=e4da151e24602, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田收购腹腔疾病疗法TAK-101：一种含有麦醇溶蛋白的免疫修饰纳米颗粒, objectType=article, longId=181776, objectId=9290181e76ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9290181e76ef, replyNumber=0, likeNumber=70, createdTime=2019-10-24, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9290181e76ef, moduleTitle=武田收购腹腔疾病疗法TAK-101：一种含有麦醇溶蛋白的免疫修饰纳米颗粒, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9290181e76ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517245, encodeId=241a151e24566, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=全球TOP20药企全新排名发布，武田将渤健挤出榜单, objectType=article, longId=180983, objectId=19881809839a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19881809839a, replyNumber=0, likeNumber=49, createdTime=2019-10-13, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19881809839a, moduleTitle=全球TOP20药企全新排名发布，武田将渤健挤出榜单, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19881809839a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517244, encodeId=b8dd151e2442a, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=NEJM：完胜Humira！武田Entyvio治疗UC的III期临床进一步结果出炉, objectType=article, longId=180261, objectId=29ed18026114, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29ed18026114, replyNumber=0, likeNumber=74, createdTime=2019-10-01, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29ed18026114, moduleTitle=NEJM：完胜Humira！武田Entyvio治疗UC的III期临床进一步结果出炉, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29ed18026114)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517243, encodeId=7eab151e24392, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田的蛋白酶抑制剂Ninlaro治疗系统性轻链淀粉样变性患者的3期临床研究失败告终, objectType=article, longId=167837, objectId=497116e837ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=497116e837ab, replyNumber=0, likeNumber=60, createdTime=2019-06-09, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=497116e837ab, moduleTitle=武田的蛋白酶抑制剂Ninlaro治疗系统性轻链淀粉样变性患者的3期临床研究失败告终, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=497116e837ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517242, encodeId=20c1151e2428d, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=3期临床试验证实，武田的整合素单抗Entyvio治疗溃疡性结肠炎优于抗肿瘤坏死因子单抗修美乐, objectType=article, longId=162132, objectId=47be16213263, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47be16213263, replyNumber=0, likeNumber=52, createdTime=2019-03-13, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47be16213263, moduleTitle=3期临床试验证实，武田的整合素单抗Entyvio治疗溃疡性结肠炎优于抗肿瘤坏死因子单抗修美乐, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47be16213263)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517241, encodeId=446b151e241ef, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田、微软和欧洲罕见病组织发布报告为罕见病患者提供行动建议, objectType=article, longId=161522, objectId=6cc0161522fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cc0161522fc, replyNumber=0, likeNumber=76, createdTime=2019-03-03, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cc0161522fc, moduleTitle=武田、微软和欧洲罕见病组织发布报告为罕见病患者提供行动建议, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6cc0161522fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517240, encodeId=ffc9151e24016, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田、创行“智慧医养美好生活”医养服务创新项目圆满结束, objectType=article, longId=157543, objectId=7d1615e54378, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d1615e54378, replyNumber=0, likeNumber=72, createdTime=2019-01-09, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d1615e54378, moduleTitle=武田、创行“智慧医养美好生活”医养服务创新项目圆满结束, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d1615e54378)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517239, encodeId=0d31151e2396b, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田与新生物技术公司Ambys合作开发肝病药物, objectType=article, longId=146266, objectId=ef1e146266e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef1e146266e3, replyNumber=0, likeNumber=78, createdTime=2018-08-11, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef1e146266e3, moduleTitle=武田与新生物技术公司Ambys合作开发肝病药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef1e146266e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517238, encodeId=fa74151e238c4, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=美消费者团体向FDA施压要求下架武田痛风药物, objectType=article, longId=141652, objectId=a51a14165264, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a51a14165264, replyNumber=0, likeNumber=66, createdTime=2018-06-28, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a51a14165264, moduleTitle=美消费者团体向FDA施压要求下架武田痛风药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a51a14165264)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517237, encodeId=3d37151e237f0, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田宣布恩莱瑞®在中国获批多发性骨髓瘤开启全口服治疗时代, objectType=article, longId=135726, objectId=5ac6135e26c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ac6135e26c6, replyNumber=0, likeNumber=63, createdTime=2018-04-20, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ac6135e26c6, moduleTitle=武田宣布恩莱瑞®在中国获批多发性骨髓瘤开启全口服治疗时代, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ac6135e26c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517236, encodeId=a120151e23645, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田发布8项Entyvio®（维多珠单抗）真实世界的积极药物数据, objectType=article, longId=122550, objectId=27ef122550da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27ef122550da, replyNumber=0, likeNumber=77, createdTime=2017-12-08, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27ef122550da, moduleTitle=武田发布8项Entyvio®（维多珠单抗）真实世界的积极药物数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27ef122550da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517235, encodeId=353e151e2358a, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=开发T细胞疗法&nbsp武田或将$1亿收购Gammadelta&nbspTherapeutics, objectType=article, longId=98383, objectId=f6769838393, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6769838393, replyNumber=0, likeNumber=53, createdTime=2017-05-12, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6769838393, moduleTitle=开发T细胞疗法&nbsp武田或将$1亿收购Gammadelta&nbspTherapeutics, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6769838393)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517234, encodeId=6a3c151e23477, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田制药52亿收购阿瑞雅德, objectType=article, longId=87411, objectId=7a548e411b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a548e411b5, replyNumber=0, likeNumber=53, createdTime=2017-01-14, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a548e411b5, moduleTitle=武田制药52亿收购阿瑞雅德, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a548e411b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

武田

2020-05-29

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田的维多珠单抗在国内获批，用于治疗中度至重度活动性溃疡性结肠炎和克罗恩病

2020-03-27

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田开始研发血浆衍生的COVID-19疗法

2020-03-07

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田宣布以3.3亿美元收购PvP Biologics，获得针对乳糜泻的I期临床药物TAK-062

2020-03-04

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田制药宣布FDA接受其补充新药申请并给予优先审查，将酪氨酸激酶抑制剂ALUNBRIG用作ALK +转移性非小细胞肺癌的一线治疗

2020-02-27

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田的Entyvio单抗皮下制剂治疗溃疡性结肠炎，惨遭FDA拒绝

2019-12-26

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田全新机制抑酸药物沃克®（富马酸伏诺拉生片）获批进入中国

2019-12-26

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田登革热疫苗在大规模的3期临床试验中有效率达80％

2019-11-09

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田收购腹腔疾病疗法TAK-101：一种含有麦醇溶蛋白的免疫修饰纳米颗粒

2019-10-24

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

全球TOP20药企全新排名发布，武田将渤健挤出榜单

2019-10-13

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

NEJM：完胜Humira！武田Entyvio治疗UC的III期临床进一步结果出炉

2019-10-01

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田的蛋白酶抑制剂Ninlaro治疗系统性轻链淀粉样变性患者的3期临床研究失败告终

2019-06-09

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

3期临床试验证实，武田的整合素单抗Entyvio治疗溃疡性结肠炎优于抗肿瘤坏死因子单抗修美乐

2019-03-13

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田、微软和欧洲罕见病组织发布报告为罕见病患者提供行动建议

2019-03-03

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田、创行“智慧医养美好生活”医养服务创新项目圆满结束

2019-01-09

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田与新生物技术公司Ambys合作开发肝病药物

2018-08-11

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

美消费者团体向FDA施压要求下架武田痛风药物

2018-06-28

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田宣布恩莱瑞®在中国获批多发性骨髓瘤开启全口服治疗时代

2018-04-20

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田发布8项Entyvio®（维多珠单抗）真实世界的积极药物数据

2017-12-08

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

开发T细胞疗法&nbsp武田或将$1亿收购Gammadelta&nbspTherapeutics

2017-05-12

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田制药52亿收购阿瑞雅德

2017-01-14

科室
- - 订阅+
  - 更多科室
工具
服务